(Q44024381)

29 November 2017

title

Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment (English)

1 reference

HIV-associated lipodystrophy

29 November 2017

main subject

anti-retroviral agent

0 references

1 reference

S Mauss

1

1 reference

29 November 2017

M Corzillius

2

1 reference

29 November 2017

E Wolf

3

1 reference

29 November 2017

A Schwenk

4

1 reference

29 November 2017

A Adam

5

1 reference

29 November 2017

H Jaeger

6

1 reference

29 November 2017

H Knechten

7

1 reference

29 November 2017

J Goelz

8

1 reference

29 November 2017

A Goetzenich

9

1 reference

29 November 2017

DAGNA Lipantiretroviral therapy study group

10

1 reference

29 November 2017

publication date

1 January 2002

1 reference

29 November 2017

1 reference

29 November 2017

volume

3

1 reference

29 November 2017

issue

1

1 reference

29 November 2017

page(s)

49-55

1 reference

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-2662.2001.00100.X

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-2662.2001.00100.X

Indinavir-associated lipodystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-2662.2001.00100.X

Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-2662.2001.00100.X

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-2662.2001.00100.X

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-2662.2001.00100.X

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-2662.2001.00100.X

Cytokines and chemokines in HIV infection: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-2662.2001.00100.X

Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-2662.2001.00100.X

Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-2662.2001.00100.X

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-2662.2001.00100.X

10.1046/J.1464-2662.2001.00100.X

21 January 2018

Identifiers

DOI

1 reference

29 November 2017

1 reference